Last reviewed · How we verify
ethinyl estradiol and cyproterone acetate
Ethinyl estradiol and cyproterone acetate is a combined oral contraceptive that suppresses ovulation through hormonal inhibition and reduces androgenic effects through anti-androgenic activity.
Ethinyl estradiol and cyproterone acetate is a combined oral contraceptive that suppresses ovulation through hormonal inhibition and reduces androgenic effects through anti-androgenic activity. Used for Oral contraception, Treatment of acne and hirsutism associated with hyperandrogenism.
At a glance
| Generic name | ethinyl estradiol and cyproterone acetate |
|---|---|
| Sponsor | S.C.B. Medical College and Hospital |
| Drug class | Combined oral contraceptive with anti-androgenic activity |
| Target | Estrogen receptor, progesterone receptor, androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception and Gynecology |
| Phase | FDA-approved |
Mechanism of action
Ethinyl estradiol is a synthetic estrogen that inhibits the luteinizing hormone (LH) surge needed for ovulation, while cyproterone acetate is a progestin with anti-androgenic properties that blocks androgen receptors. Together, they prevent pregnancy and reduce symptoms of hyperandrogenism such as acne and hirsutism by suppressing ovulation and antagonizing androgen signaling.
Approved indications
- Oral contraception
- Treatment of acne and hirsutism associated with hyperandrogenism
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Venous thromboembolism
- Hypertension
Key clinical trials
- Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (NA)
- GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (PHASE2, PHASE3)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
- "Effect of CPA/EE Drug on Periodontal Tissue and hsCRP Levels in PCOS Patients With Gingivitis
- Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa (PHASE3)
- Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety (NA)
- Phlebotomy and Polycystic Ovary Syndrome (NA)
- The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: